OSUR Key Statistics, Chart & Performance
The current stock price of OSUR is 2.63 USD. In the past month the price increased by 3.14%. In the past year, price decreased by -27.35%.
OSUR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.21 | 16.59B | ||
| SOLV | SOLVENTUM CORP | 14.5 | 14.94B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.87 | 12.40B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.22 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.34 | 4.48B | ||
| HAE | HAEMONETICS CORP/MASS | 17.09 | 3.84B | ||
| ICUI | ICU MEDICAL INC | 19.22 | 3.78B | ||
| XRAY | DENTSPLY SIRONA INC | 8.09 | 2.55B | ||
| NEOG | NEOGEN CORP | 33.17 | 2.09B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.84 | 1.99B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.3 | 746.59M |
Related stock screener links
About OSUR
Company Profile
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 501 full-time employees. The firm improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
Company Info
ORASURE TECHNOLOGIES INC
220 E First St
Bethlehem PENNSYLVANIA 18015 US
CEO: Stephen S. Tang
Employees: 501
Phone: 15036416115
ORASURE TECHNOLOGIES INC / OSUR FAQ
What does ORASURE TECHNOLOGIES INC do?
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 501 full-time employees. The firm improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
What is the stock price of ORASURE TECHNOLOGIES INC today?
The current stock price of OSUR is 2.63 USD. The price decreased by -1.13% in the last trading session.
What is the dividend status of ORASURE TECHNOLOGIES INC?
OSUR does not pay a dividend.
How is the ChartMill rating for ORASURE TECHNOLOGIES INC?
OSUR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in ORASURE TECHNOLOGIES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OSUR.
What is the next earnings date for OSUR stock?
ORASURE TECHNOLOGIES INC (OSUR) will report earnings on 2026-02-23, after the market close.
OSUR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OSUR. When comparing the yearly performance of all stocks, OSUR is a bad performer in the overall market: 85.67% of all stocks are doing better.
OSUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSUR. The financial health of OSUR is average, but there are quite some concerns on its profitability.
OSUR Financial Highlights
Over the last trailing twelve months OSUR reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS decreased by -633.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.24% | ||
| ROE | -16.64% | ||
| Debt/Equity | 0 |
OSUR Forecast & Estimates
9 analysts have analysed OSUR and the average price target is 4.59 USD. This implies a price increase of 74.52% is expected in the next year compared to the current price of 2.63.
For the next year, analysts expect an EPS growth of -239.35% and a revenue growth -38.37% for OSUR